RPRX
Royalty Pharma Plc
56.80$
+0.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106.9% | 129.6% | 117.0% | 122.5% | 124.6% | 125.1% | 104.9% | 62.9% | 115.3% | 133.0% | 120.6% | 101.8% | 117.4% | |
| 0.0% | 0.0% | – | 0.8% | -0.8% | – | 0.0% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | |
| 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 15.7% | 12.0% | 20.2% | 19.3% | 15.9% | 16.9% | |
| -6.9% | 8.0% | -5.2% | 9.3% | -3.3% | 8.7% | -11.3% | 8.6% | -8.4% | 7.8% | 132.4% | -247.8% | -33.0% | |
| 84.1% | 168.1% | 15.2% | 139.0% | 147.5% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| -84.0% | -167.8% | -15.3% | -166.2% | -211.2% | -85.2% | 88.7% | -53.9% | -157.3% | -136.3% | -82.5% | -27.8% | -99.1% | |
| 16.7% | 15.0% | 16.5% | 17.7% | 16.7% | 15.8% | 16.8% | 16.1% | 15.6% | 15.2% | 16.6% | 15.6% | 15.7% | |
| -26.1% | -5.1% | 0.0% | -14.9% | -17.2% | -8.9% | -124.7% | -50.4% | -24.0% | -12.9% | -7.9% | -6.6% | -12.7% | |
| – | – | – | – | 0.0% | 0.0% | – | – | 156.7% | 0.0% | – | – | – | |
| -253.5% | -38.9% | -37.3% | 215.3% | -57.6% | -43.5% | -165.6% | -87.8% | 92.4% | -48.2% | -43.2% | -40.5% | -11.1% | |
| -230.6% | -77.1% | 64.4% | 171.5% | -144.3% | -3.5% | 27.9% | -78.8% | 50.4% | -51.5% | -5.1% | 33.5% | 7.1% | |
| 106.9% | 129.6% | 117.0% | 122.5% | 124.6% | 125.1% | 104.9% | 62.9% | 115.3% | 133.0% | 120.6% | 101.8% | 117.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.